The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | ADCs in the NHL treatment landscape
Moshe Y. Levy, MD, Baylor University Medical Center, Dallas, TX, gives an overview of the use of antibody-drug conjugates (ADC) in non-Hodgkin lymphoma (NHL). Replacing vincristine in R-CHOP, the standard of care for NHL, with the anti-CD47 polatuzumab vedotin have proven to be as effective as the original R-CHOP in clinical trials, and the anti-CD19 loncastuximab tesirine has additionally demonstrated promising efficacy in patients. The two ADCs have also reported to have a favorable toxicity profile, with fewer cases of liver toxicity and neuropathy seen. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Dr Levy reports consultant/speaker fees from: Abbvie, Amgen, BMS, Janssen, Karyopharm, Morphosys, Seattle genetics, Takeda, Astra Zeneca, Beigene, Gilead, Jazz, TG therapeutics, Dova, Epizyme, GSK, and Novartis.
